RBC Capital Initiates Pfizer (PFE) with $25 Target, Warns of Structural Revenue Headwinds

Core Viewpoint - Pfizer Inc. is facing significant revenue challenges, with an expected decline of $15 billion to $20 billion through 2030, and limited visibility into new products to offset these losses [2] Group 1: Analyst Ratings and Financial Outlook - RBC Capital initiated coverage of Pfizer with an Underperform rating and a price target of $25, citing structural revenue headwinds [2] - The firm noted that Pfizer's dividend yield of approximately 6% is above the peer average, providing some support, but may not be sufficient to counter deeper challenges [2] - Analysts see a lack of meaningful catalysts for Pfizer heading into 2026 [2] Group 2: Licensing Agreement and Market Expansion - Pfizer signed a licensing agreement with Sciwind Biosciences for its type 2 diabetes drug, ecnoglutide, which could yield up to $495 million in milestone payments [3] - The partnership is aimed at expanding Pfizer's presence in China's metabolic disease market, where ecnoglutide, a GLP-1 receptor agonist, is gaining interest [4] - Ecnoglutide received approval in China in January, and Sciwind has submitted an application for a weight management version [5] Group 3: Competitive Landscape - Ecnoglutide will not be covered under China's national health insurance program for diabetes treatment, unlike competing GLP-1 drugs such as Novo Nordisk's Ozempic and Eli Lilly's Mounjaro [6] - The GLP-1 receptor agonist category is attracting significant investment from various companies, indicating a competitive market environment [4]